Here's What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT)
Is Sarepta Therapeutics Inc (NASDAQ:SRPT) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
News
- First
- << Previous
- 71 - 80
- Next >>
Here is What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT)
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC.
Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without...
Hedge Funds Just Stormed Into This Red-Hot Biotech Company
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not...
The 25 Biggest Insider Purchases in October
Insider purchases consistently outpaced insider sales during much of October, the first time that has happened over a minimum two-week period since January 2016.
Here's How This Week Has Started For The Financial Markets
"U.S. stocks rose on Monday, boosted by technology shares and by defense companies, which rose after the United States and Saudi Arabia signed a multi-billion dollar arms deal.
Here's What Is Going On In The Financial Markets Today?
"U.S. stocks traded firmly higher Wednesday, with the Nasdaq Composite setting an intraday record, after a strong reading on private-sector hiring in March.
Why Sarepta Therapeutics Inc (SRPT) Shares Are Surging
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares have popped 4% after Edward Nash of SunTrust upgraded the equity to 'Buy' from 'Hold' and set a $45 target price.
What Do Hedge Funds Think of Sarepta Therapeutics Inc (SRPT)?
At this point, Sarepta Therapeutics Inc (NASDAQ:SRPT) shares look range-bound since late December. Investors are eager for to analyze any Exondys 51 sales data that comes out.
Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen
Sarepta Therapeutics Inc (NASDAQ:SRPT) is one of the week’s biggest winners from the J.P.
- First
- << Previous
- 71 - 80
- Next >>
Billionaire Hedge Funds
